The effect of theophylline in the treatment of bronchiectasis, a random, double blind study

The effect of theophylline in the treatment of bronchiectasis, a random, double blind study.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002470

Enrollment

Unknown

Registered

2012-08-02

Start date

2012-09-15

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bronchiectasis not due to cystic fibrosis

Interventions

1:theophylline

2:theophylline

Eligibility

Sex/Gender

All

Age

15 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients between 18-65 years old with non-CF bronchiectasis,free from acute exacerbations for at least 3 months.

Exclusion criteria

Exclusion criteria: Patients with a cigarette smoking history of more than 10 packs-year; Patients with COPD; Patients with traction bronchiectasis due to advanced fibrosis; Patients with known intolerance for IC or theophylline; Patients with asthma; patients with other disease disturbing outcomes of the trials.

Design outcomes

Primary

Measure	Time frame
St George's Respiratory Questionnaire;lung function;days needed SABA;Sputum culture;	—

Secondary

Measure	Time frame
Routine blood test;ESR;Induced sputum cytology count;IL-6;IL-8;TNF-alpha;Isoprostane;activity of HDAC;activity of HDTC;CRP;The Leicester Cough Questionnaire;24 hour sputum volume;the number of exacerbations;	—

Countries

China

Contacts

Public ContactChen Rongchang

chenrc@vip.163.com+86 13902273260

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026